Feasibility of home dose optimization of apomorphine sublingual film in Parkinson's disease patients with OFF episodes: results from the dose-optimization phase of an open-label, randomized crossover study.

ABSTRACT:

Background

Dose optimization of sublingual apomorphine (SL-APO), a dopamine agonist for the treatment of OFF episodes in patients with Parkinson's disease (PD), has been performed under clinical supervision in clinical trials. SL-APO may be a candidate for home dosing optimization which would be less burdensome for patients.

Objectives

To evaluate the feasibility and safety of home optimization of SL-APO in patients with PD and OFF episodes.

Design

A multicenter, randomized, crossover study comparing SL-APO with subcutaneous apomorphine was conducted, comprising an open-label dose-optimization phase and a treatment phase. This non-comparative analysis focuses on the outcomes of the dose-optimization phase with SL-APO only.

Methods

Patients with PD and OFF episo

SUBMITTER: Kassubek J 

PROVIDER: S-EPMC10637145 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature